These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Barak S; Weiner I Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109 [TBL] [Abstract][Full Text] [Related]
7. Novel pharmacological approaches to the treatment of schizophrenia. Fink-Jensen A Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983 [TBL] [Abstract][Full Text] [Related]
8. Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice. Thomsen M; Wörtwein G; Fink-Jensen A; Woldbye DP; Wess J; Caine SB Psychopharmacology (Berl); 2007 May; 192(1):97-110. PubMed ID: 17310388 [TBL] [Abstract][Full Text] [Related]
10. Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Gronier B; Rasmussen K Br J Pharmacol; 1998 Jun; 124(3):455-64. PubMed ID: 9647468 [TBL] [Abstract][Full Text] [Related]
11. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline. Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215 [TBL] [Abstract][Full Text] [Related]
13. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. Li Z; Snigdha S; Roseman AS; Dai J; Meltzer HY Eur J Pharmacol; 2008 Oct; 596(1-3):89-97. PubMed ID: 18771666 [TBL] [Abstract][Full Text] [Related]
14. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Paul SM; Yohn SE; Popiolek M; Miller AC; Felder CC Am J Psychiatry; 2022 Sep; 179(9):611-627. PubMed ID: 35758639 [TBL] [Abstract][Full Text] [Related]
15. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Dean B Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751 [TBL] [Abstract][Full Text] [Related]
16. The neurobiology of cognition in schizophrenia. Tamminga CA J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183 [TBL] [Abstract][Full Text] [Related]
19. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Svensson TH Brain Res Brain Res Rev; 2000 Mar; 31(2-3):320-9. PubMed ID: 10719159 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous activation of muscarinic and GABA Cieślik P; Woźniak M; Tokarski K; Kusek M; Pilc A; Płoska A; Radulska A; Pelikant-Małecka I; Żołnowska B; Sławiński J; Kalinowski L; Wierońska JM Behav Brain Res; 2019 Feb; 359():671-685. PubMed ID: 30267715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]